Hypoxic Hepatitis: A Review and Clinical Update.

Area of Science:

• Hepatology
• Critical Care Medicine

Background:

• Hypoxic hepatitis (HH), also known as ischemic hepatitis or shock liver, is a condition marked by a rapid, significant rise in serum aminotransferases.
• It stems from insufficient oxygen delivery to the liver, often linked to cardiac failure, septic shock, or respiratory failure.

Approach:

• Diagnosis is primarily clinical, relying on patient presentation and laboratory findings, often without requiring a liver biopsy.
• Pathophysiology is multifactorial, involving hepatic congestion, reduced hepatic blood flow, systemic hypoxemia, and potential reperfusion injury.

Key Points:

• HH occurs in 50% of patients without a documented hypotensive event.
• Incidence in ICUs is approximately 2.5%, potentially reaching 10% in some studies.
• Management involves addressing the underlying condition and monitoring for complications like hypoglycemia, hyperglycemia, hyperammonemia, and hepatopulmonary syndrome.

Conclusions:

• The prognosis for HH is poor, with in-hospital mortality exceeding 50%.
• Delayed diagnosis is associated with a worse outcome.
• Death is typically attributed to the predisposing condition rather than the liver injury itself.